[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340229-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340229-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-and-predictive-factors-in-advanced-upper-gastrointestinal-cancer-treated-with-immune-checkpoint-inhibitors-a-systematic-review-and-meta-analysis-of-the-current-evidence","Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors - A systematic review and meta-analysis of the current evidence","","Immune checkpoint inhibitors (ICIs) have shown encouraging efficacy for upper gastrointestinal cancers, yet durable responses occur only in a minority of patients. This systematic review and meta-analysis evaluated clinical-trial evidence to identify biomarkers and clinical features that predict survival benefit from ICI-based therapy. Databases including PubMed, Embase, Cochrane Library, and Web of Science were searched, and outcomes were assessed by objective response rate, progression-free survival, and overall survival using GRADE quality evaluation.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-and-predictive-factors-in-advanced-upper-gastrointestinal-cancer-treated-with-immune-checkpoint-inhibitors-a-systematic-review-and-meta-analysis-of-the-current-evidence/340229/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-and-predictive-factors-in-advanced-upper-gastrointestinal-cancer-treated-with-immune-checkpoint-inhibitors-a-systematic-review-and-meta-analysis-of-the-current-evidence/340229.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-28","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Which factors were associated with better response to ICI treatment in advanced upper gastrointestinal cancer?","Question",{"text":63,"@type":64},"Patients with PD-L1-positive tumors and EBV+ status were more likely to respond to ICI therapy, according to pooled quantitative synthesis results.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was survival benefit assessed in the review?",{"text":68,"@type":64},"The study evaluated objective response rate, progression-free survival, and overall survival, and assessed evidence quality using GRADE.",{"name":70,"@type":61,"acceptedAnswer":71},"Did the review find differences in overall survival benefits by subgroup?",{"text":72,"@type":64},"Yes. Overall survival improvements varied by sex and region, and exploratory analyses suggested additional benefit for patients receiving ICI plus chemotherapy at higher CPS thresholds.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340229,1790644404,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Wang et al. BMC Cancer (2024) 24:1249 BMC Cancer  \n[https://doi.org/10.1186/s12885-024-12998-w](https://doi.org/10.1186/s12885-024-12998-w)  \nRESEARCH Open Access  \nPrognostic and predictive factors in advanced upper gastrointestinal cancer treated  \nwith immune checkpoint inhibitors: a systematic review and meta-analysis of the current evidence  \nPuxiu Wang 1,2†, Ping Chen 1,2†, Weiting Yang 1,2, Wenhan Yang 1,2, Wenqi Liu3, Song Yue 1,2* and Qiuhua Luo 1,2*  \nAbstract  \nBackground Immune checkpoint inhibitors (ICIs) have shown encouraging treatment efficacy for upper gastrointestinal cancers (UGICs) . However, durable clinical responses only existed in a minority of patients. We evaluated evidence predicting survival benefits to identify the optimal population followed by ICI-based therapy. Methods A comprehensive search was performed using PubMed, Embase, Cochrane Library, and Web of Science to identify clinical trials for UGICs with ICI-based therapy. The outcomes were objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) . The quality of evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation System (GRADE) .  \nResults Thirty-six studies comprising 12,440 patients were included for quantitative synthesis. Patients with PD-L1-positive (OR = 2 . 08, p \u003C 0. 00001), EBV+ (OR = 8 .47, p = 0 . 003) tumors were more likely to respond to ICI treatment. Moreover, OS was significantly improved with the statistical subgroup difference concerning sex (p = 0 . 02) and region (p = 0 . 02) . An exploratory subgroup analysis showed significantly improved OS with ICI plus chemotherapy in patients with CPS ≥ 10 (HR = 0 . 66, p = 0 . 001) and CPS ≥ 1 (HR = 0 . 75, p \u003C 0. 00001) .  \nConclusion UGIC patients with PD-L1-positive, EBV + status are associated with a better therapeutic response to ICI-based therapy. The male patients and Asian patients could derive more survival benefits following ICI treatment than female and non-Asian ones. A combination of prognostic and predictive factors was suggested to help guide immunotherapy decision-making in UGIC patients.  \nKeywords Upper gastrointestinal cancer, Immune checkpoint inhibitor, Biomarker, Prognosis, Overall survival  \n†Puxiu Wang and Ping Chen are co-first authors.  \n*Correspondence: Song Yue [yuesong567@163.com](yuesong567@163.com)[ ](yuesong567@163.com)Qiuhua Luo [qhluo@cmu.edu.cn](qhluo@cmu.edu.cn)  \n1Department of Pharmacy, The First Hospital of China Medical University, Shenyang, Liaoning, PR China  \n2School of Pharmacy, China Medical University, Shenyang, Liaoning, PR China  \n3School of Life Sciences, Shenyang Pharmaceutical University, Shenyang, Liaoning, PR China  \n© The Author(s) 2024. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://](http://)[ ](http://)[creativecommons.org/l](creativecommons.org/l)icenses/by-nc-nd/4.0/.  \nIntroduction  \nUpper gastrointestinal cancers (UGICs), including esophageal cancer (EC), gastroesophageal junction cancer (GEJC) and gastric cancer (GC), are among th","cbCail7pUxn2n3qR","https://ap.wps.com/l/cbCail7pUxn2n3qR","pdf",4727483,16,"English","# Abstract\n# Introduction\n## Clinical background of upper gastrointestinal cancers\n## Rationale for immune checkpoint inhibitors\n# Methods and evidence evaluation\n## Literature search strategy\n## Outcomes and quality assessment\n# Results\n## Predictive factors for response\n## Survival benefits across subgroups\n# Conclusion","[{\"question\":\"Which factors were associated with better response to ICI treatment in advanced upper gastrointestinal cancer?\",\"answer\":\"Patients with PD-L1-positive tumors and EBV+ status were more likely to respond to ICI therapy, according to pooled quantitative synthesis results.\"},{\"question\":\"How was survival benefit assessed in the review?\",\"answer\":\"The study evaluated objective response rate, progression-free survival, and overall survival, and assessed evidence quality using GRADE.\"},{\"question\":\"Did the review find differences in overall survival benefits by subgroup?\",\"answer\":\"Yes. Overall survival improvements varied by sex and region, and exploratory analyses suggested additional benefit for patients receiving ICI plus chemotherapy at higher CPS thresholds.\"}]","Prognostic and predictive factors in advanced upper gastrointestinal cancer treated with immune checkpoint inhibitors - A systematic review and meta-analysis of the current evidence | PDF",1790035067,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f05c077c495cefd4c37d5556f890ce3.webp",983,1310,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b68d2f8588357d46bdcf751b0282c0f.webp",982,1309,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c912b0f8661dc1d578021610e8081d42.webp",981,1308,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dfedffab108624134f2d035dc27176bb.webp",980,1306]